RMD Quote, Financials, Valuation and Earnings

iRhythm Technologies has a net margin of 28.26% compared to ResMed's net margin of -19.35%. ResMed's return on equity of 25.76% beat iRhythm Technologies's return on equity of -112.03%.

ResMed has a consensus price target of $269.49, signalling upside risk potential of 5.99%. On the other hand iRhythm Technologies has an analysts' consensus of $145.67 which suggests that it could grow by 6.33%. Given that iRhythm Technologies has higher upside potential than ResMed, analysts believe iRhythm Technologies is more attractive than ResMed.

ResMed has a beta of 0.774, which suggesting that the stock is 22.603% less volatile than S&P 500. In comparison iRhythm Technologies has a beta of 1.413, suggesting its more volatile than the S&P 500 by 41.267%.

ResMed has a quarterly dividend of $0.53 per share corresponding to a yield of 0.83%. iRhythm Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed pays 27.65% of its earnings as a dividend. iRhythm Technologies pays out -- of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.3B, which are larger than iRhythm Technologies quarterly revenues of $158.7M. ResMed's net income of $365M is higher than iRhythm Technologies's net income of -$30.7M. Notably, ResMed's price-to-earnings ratio is 28.54x while iRhythm Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 7.47x versus 6.94x for iRhythm Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 28.26% compared to ResMed's net margin of -45.89%. ResMed's return on equity of 25.76% beat Masimo's return on equity of -39.91%.

ResMed has a consensus price target of $269.49, signalling upside risk potential of 5.99%. On the other hand Masimo has an analysts' consensus of $184.37 which suggests that it could grow by 15.63%. Given that Masimo has higher upside potential than ResMed, analysts believe Masimo is more attractive than ResMed.

ResMed has a beta of 0.774, which suggesting that the stock is 22.603% less volatile than S&P 500. In comparison Masimo has a beta of 1.187, suggesting its more volatile than the S&P 500 by 18.716%.

ResMed has a quarterly dividend of $0.53 per share corresponding to a yield of 0.83%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed pays 27.65% of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.3B, which are larger than Masimo quarterly revenues of $372M. ResMed's net income of $365M is higher than Masimo's net income of -$170.7M. Notably, ResMed's price-to-earnings ratio is 28.54x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 7.47x versus 4.38x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 28.26% compared to ResMed's net margin of 6.22%. ResMed's return on equity of 25.76% beat Insulet's return on equity of 36.9%.

ResMed has a consensus price target of $269.49, signalling upside risk potential of 5.99%. On the other hand Insulet has an analysts' consensus of $336.85 which suggests that it could grow by 16.85%. Given that Insulet has higher upside potential than ResMed, analysts believe Insulet is more attractive than ResMed.

ResMed has a beta of 0.774, which suggesting that the stock is 22.603% less volatile than S&P 500. In comparison Insulet has a beta of 1.346, suggesting its more volatile than the S&P 500 by 34.619%.

ResMed has a quarterly dividend of $0.53 per share corresponding to a yield of 0.83%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed pays 27.65% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.3B, which are larger than Insulet quarterly revenues of $569M. ResMed's net income of $365M is higher than Insulet's net income of $35.4M. Notably, ResMed's price-to-earnings ratio is 28.54x while Insulet's PE ratio is 51.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 7.47x versus 9.70x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Semler Scientific has a net margin of 28.26% compared to ResMed's net margin of -732.34%. ResMed's return on equity of 25.76% beat Semler Scientific's return on equity of -23.56%.

ResMed has a consensus price target of $269.49, signalling upside risk potential of 5.99%. On the other hand Semler Scientific has an analysts' consensus of $98.00 which suggests that it could grow by 129.46%. Given that Semler Scientific has higher upside potential than ResMed, analysts believe Semler Scientific is more attractive than ResMed.

ResMed has a beta of 0.774, which suggesting that the stock is 22.603% less volatile than S&P 500. In comparison Semler Scientific has a beta of 1.392, suggesting its more volatile than the S&P 500 by 39.164%.

ResMed has a quarterly dividend of $0.53 per share corresponding to a yield of 0.83%. Semler Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed pays 27.65% of its earnings as a dividend. Semler Scientific pays out -- of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.3B, which are larger than Semler Scientific quarterly revenues of $8.8M. ResMed's net income of $365M is higher than Semler Scientific's net income of -$64.7M. Notably, ResMed's price-to-earnings ratio is 28.54x while Semler Scientific's PE ratio is 8.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 7.47x versus 7.32x for Semler Scientific. Usually stocks with elevated PS ratios are considered overvalued.